A simple and quick ultra performance liquid chromatography method (UPLC) has been developed for determination of methyl paraben (MP) and its major metabolites p-hydroxybenzoic acid (pHBA) and phenol (Phe), following its biotransformations in Eisenia foetida. After different exposure time to paper contact test, the presence of methyl paraben and his biotransformation products in adult earthworms was monitored. Determination of its metabolites was achieved with a BEH (bridged ethane-silicon hybrid) C 18 column (2.1×50 mm i.d., 1.7 µm particle size), using methanol/water/phosphoric acid as mobile phase, under a gradient elution program, and a PDA (photo-diode array) detection (quantification with MaxPlot in the range 210-400 nm). The absorption of MP did not exceed 30% and in the first 4-6 h after exposure only minute amounts of pHBA and Phe were detected in the worm homogenates. After 48 h of exposures, almost 70% of absorbed MP was already metabolized to Phe and around 20% could be found as pHBA.
Introduction. Viral hepatitis C (HCV) is a significant global health problem. The risk of developing chronic HCV is up to 80% of patients, of whom 10-20% can develop liver cirrhosis or hepatocellular carcinoma which can lead to death. Treatment with direct-acting antiviral agents (DAAs) contributes to a sustained virological response (SVR) in 97-99% of cases. Material and methods. The study was conducted on 206 patients with chronic HCV who underwent two generic antiviral agent therapies: group I (103)-Sofosbuvir 400 mg + Ledipasvir 80 mg, whereas group II (103)-Sofosbuvir 400 mg + Daclatasvir 60 mg orally, once a day, for 12 weeks. The assessment of hepatitis C virus RNA and genotype, as well as the degree of hepatic fibrosis by Fibroscan, biochemical and complete blood count (CBC) indices were carried out. Results. The study results showed high efficacy of the generic DAAs treatment in patients with chronic HCV over 12 weeks. The SVR rate made up 90.3% in Sofosbuvir + Ledipasvir therapy and 86.4%-in Sofosbuvir + Daclatasvir. Similar treatment response was recorded in naive patients and those who previously underwent unsuccessful treatment with Pegylated Interferon and Ribavirin. The DAAs treatment showed the following minor adverse reactions: asthenia, headache, sleep disorder, and nausea, which did not require treatment discontinuation. Conclusions. The 12-week course of DAAs therapy exhibited high SVR rate in both chronic HCV naive patients and those previously treated with Pegylated Interferon and Ribavirin.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.